Genetic Testing Recommended for Children Considered at Risk for Most Common Eye Cancer

SAN FRANCISCO, Oct. 18, 2017 /PRNewswire-USNewswire/ -- Children who are considered to be at risk of developing eye cancer should receive genetic counseling and testing as soon as possible to clarify risk for the disease. This is the consensus of leading ophthalmologists, pathologists and geneticists, who worked for two years to develop the first U.S. guidelines on how to screen for the most common eye tumor affecting children. The goal is to ensure retinoblastoma is detected at the earliest possible stage so ophthalmologists can save the lives and vision of more children. The guidelines are being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology.

Retinoblastoma is a cancer that starts in the retina, the very back of the eye. It can also spread to other parts of the body, including the brain and bones. There are approximately 350 new cases diagnosed each year in the United States.

The disease primarily affects young children. It can be either hereditary or non-hereditary. Children with hereditary retinoblastoma often develop retinal tumors in both eyes within the first years of life. Early diagnosis, when tumors are small, improves the child's chance of survival and their chance of keeping their vision and their eyes.

Development of these guidelines began when ophthalmologist Alison Skalet, M.D., Ph.D., of the Casey Eye Institute in Portland, Ore., searched for an optimal screening strategy for her own patients and found little published guidance.

For the next two years, Dr. Skalet and Patricia Chévez-Barrios, M.D., ophthalmologist, and pathologist from Houston Methodist Hospital, led members of the American Association of Ophthalmic Oncologists and Pathologists, and a team of experts to devise guidelines¹. The effort was also supported by the American Association for Pediatric Ophthalmology and Strabismus, the American Academy of Ophthalmology, and the American Academy of Pediatrics.

The guidelines address a knowledge gap among ophthalmologists and other health care professionals in the U.S. regarding risk for inherited retinoblastoma and best practices for screening examinations. It is anticipated that they will also influence care in other countries. Therefore, the guidelines were written to provide a general framework for care that can be modified based on local resources, and provider and parental preferences. The recommendations acknowledge pediatric anesthesia and genetic testing may be limited in many developing countries, preventing strict adherence. So, the guidelines offer direction in cases when these resources are unavailable.

Dr. Chévez-Barrios said the new guidelines meet the team's goal to focus care on children at the highest risk for disease while decreasing unnecessary examinations for children at lower or no risk of developing retinoblastoma.

"We wanted to make sure all the doctors who come in contact with these patients are aware of how to diagnose and treat them so we can save more eyes, more vision and of course more lives," said Dr. Chévez-Barrios.

Ophthalmologists say there are signs to look for that may indicate retinoblastoma. They include a white color in the pupil when a light is shone in the eye, such as when taking a flash photograph. Also, eyes that appear to be looking in different directions could be a sign of trouble. They encourage parents to make an appointment with their child's pediatrician if they notice any changes to their child's eyes.

About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world's largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart^® program provides the public with the most trusted information about eye health. For more information, visit aao.org.

¹The panel consisted of ophthalmologists, pathologists, and geneticists from leading cancer centers around the U.S. and Canada. In addition to Drs. Skalet and Chévez-Barrios, the panel included: Dan Gombos, M.D. and Sharon Plon M.D., PhD from the Retinoblastoma Center of Houston; Jonathan Kim, M.D., from Children's Hospital Los Angeles, California; Carol Shields, M.D., from Wills Eye Hospital in Philadelphia; Brian Marr, M.D., from New York-Presbyterian/Columbia University Medical Center, and Memorial Sloan Kettering Cancer Center, New York; and Brenda Gallie, M.D., from The Hospital for Sick Children, Ontario, Canada.

SOURCE American Academy of Ophthalmology

Related Links

http://www.aao.org